Disease progression and response to therapy in pemphigus based on a registryJosquin Pieper, Michael Hertl, Brandon Greene et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2022Cited by 6
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Michael Hertl, Christoph Hudemann et al.|British Journal of Dermatology|2025Cited by 5
Register‐Studie zu Krankheitsentwicklung und Therapieansprechen bei PemphigusJosquin Pieper, Michael Hertl, Robert Pollmann et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2022Cited by 1